Revolo Shares New Preclinical Data Showcasing the Potential of Sublingual ‘1104 in Allergic Disease
21 oct. 2024 08h30 HE
|
Revolo Biotherapeutics
Sublingual (SL) formulation of ‘1104 achieved comparable responses to subcutaneous (SQ) and intravenous (IV) injections‘1104 SC and SL dosing options create opportunities for highly differentiated...
Revolo Announces New Preclinical Data Further Validating Atopic Dermatitis as a Target Indication for ‘1104
18 sept. 2024 08h45 HE
|
Revolo Biotherapeutics
Data continues to differentiate ‘1104 as a potential allergic disease treatment that acts upstream in the immune cascade‘1104 reduces key indices of skin inflammation and inflammatory mediators in a...
Revolo Announces Fireside Chat at Canaccord Genuity’s 44th Annual Growth Conference
07 août 2024 08h45 HE
|
Revolo Biotherapeutics
GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics Limited (“Revolo”) today announced that President and Chief Executive Officer, Woody Bryan,...
Revolo Announces New Data Further Validating the Upstream Mechanism of Action and Subcutaneous Administration of ‘1104
24 juil. 2024 08h45 HE
|
Revolo Biotherapeutics
Reduction of key proteins in the interleukin 4 (IL-4) and IL-13 signalling pathway via SHP-1 activation is a key component involved in the mechanism of action of ‘1104First-in-class upstream approach...
Revolo Biotherapeutics to Present at Upcoming Medical Meetings in May
14 mai 2024 08h00 HE
|
Revolo Biotherapeutics
GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, May 14, 2024 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to...
Revolo Biotherapeutics Receives Orphan Drug Designation from the U.S. FDA for its First-in-Class Peptide as a Potential Treatment for Eosinophilic Esophagitis
30 janv. 2024 08h30 HE
|
Revolo Biotherapeutics
GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to...
Revolo Biotherapeutics Presents New Data on ‘1805 at the American College of Rheumatology Convergence 2023 Annual Conference
07 nov. 2023 10h05 HE
|
Revolo Biotherapeutics
- New preclinical data further elucidate ‘1805’s mechanism of action in rheumatoid arthritis (RA) - NEW ORLEANS and CAMBRIDGE, United Kingdom, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Revolo...
Revolo Biotherapeutics Announces Data from Study of ‘1104 in Atopic Adults
25 oct. 2023 08h00 HE
|
Revolo Biotherapeutics
- Treatment with ‘1104 demonstrated a rapid reduction in intradermal allergic inflammation - - Treatment with ‘1104 induced sustained activation of T regulatory and B regulatory cells, providing...
Revolo Biotherapeutics to Present Data from Phase 2a Clinical Trial of ‘1104 in Eosinophilic Esophagitis at ACG 2023
17 oct. 2023 08h00 HE
|
Revolo Biotherapeutics
NEW ORLEANS and CAMBRIDGE, United Kingdom, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to...
Revolo Biotherapeutics Announces the Completion of Phase 1 Multiple Ascending Dose Clinical Trial of ‘1104
21 sept. 2023 08h00 HE
|
Revolo Biotherapeutics
NEW ORLEANS and CAMBRIDGE, United Kingdom, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to...